International comparison of incentive policies for orphan drug and its enlightenment to ChinaXIN Xiao-xiong, GUAN Xiao-dong, SHI Lu-wen605-609
Several issues about Chinese legal definition of new chemical entity under the framework of data protection regimeDING Jin-xi, REN Hong-ye, YAO Xue-fang, XU Zhuo-huan610-615,621
Theoretical and empirical research on employment effect of new drug research and developmentMENG Guang-xing616-621
Validation of an assessment tool for evaluating the implementation of WHO GMP standards by Chinese manufacturers of active pharmaceutical ingredients (APIs)HUANG Bao-bin, SUN Xin-sheng, XU Ming-zhe, BAI Dong-ting, WU Zhi-ang, WU Chunfu622-626
Introduction of guideline for non-clinical safety evaluation of pediatric drug products from FDAGUANG Hong-mei, WANG Qing-li627-631
Preparation and in vitro release of rotigotine-loaded implantsLIU Yan-xiang, WANG Ai-ping, XU Meng-meng, ZHANG Xiao-xi, WANG Wen-yan, LIU Wan-hui632-637,648
Screening, construction and expression of human anti-BLyS ScFv antibody钱尼良, 张晶, 高柳村, 万德有, 冯红茹, 刘蕴慧, 杨懿, 高新, 宋海峰638-643
Application progress of Ussing chamber in intestinal absorptionLIU Xiao-lei, ZHANG Li, GU Xing, ZHU Yun, LIU Zhi-dong, LIU Yang, HU Li-min644-648